Table 1.

Abstracts of papers for pCDs used as drug delivery vehicles.

Formulations	Drugs Carried	Application Effect	System Size	Ref.
PGAβCyD	Doxorubicin	Inhibit tumor tissue growth, Reduce the side effects of doxorubicin	5.5 nm	[47]
PGAγCyD.	Doxorubicin	Inhibit tumor tissue growth, Reduce the side effects of doxorubicin	5.5 nm	[47]
CD/BP	Bisphosphonate	Treat parasitic diseases	ND	[121]
sMC	Ciprofloxacin	Improve the solubility and release of the drug	400–900 nm	[124]
HPG-β-CD	Doxorubicin	Reduce the side effects of doxorubicin	30 nm	[125]
DBASC	Doxorubicin	Inhibit tumor tissue growth, Reduce the side effects of doxorubicin	10.0–11.0 nm	[126]
PN-β-CD	Real drug cell drugs	Non-toxic, drug-acceptable, low-cost, and environmentally friendly carrier	ND	[129]
CD-NH2/Dox	Doxorubicin	Treatment of neuroblastoma	3.2 nm	[130]
pCDs	AmB	Treatment of clinical fungus	2–15 kDa	[131]
β-CD-(PLA-PDMAEMA-PEtOxMA)21	Doxorubicin	Inhibit tumor tissue growth	27–28 nm	[132]
CCSP	Doxorubicin	Reduce drug leakage and increase drug load content	40–50 nm	[133]
Polymer—cyclodextrin conjugate	Polymer—paclitaxel conjugate	Confer high stability to the nano-assembly	54.6 ± 11.6 nm	[134]
pCD polyrotaxane	interleukin 12	Protective packaging	193 ± 6.2 nm	[135]
β-CD/Pluronic P123-based polyrotaxane	β-CD	Treating NPC	29,000 Da	[136]